XML 15 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

The following provides information regarding "Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, each a 10b5-1 Plan) adopted or terminated during the three months ended March 31, 2025 by any director or officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934 (Section 16 Director or Officer):

Anish Bhatnagar, our Chief Executive Officer and Chairman of our board of directors adopted a 10b5-1 Plan on September 6, 2024. Mr. Bhatnagar's 10b5-1 Plan provided for the potential sale of up to 300,000 shares of our common stock, and was set to expire on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. Dr. Bhatnagar terminated this 10b5-1 plan on January 14, 2025.

Jim Mackaness, our Chief Financial Officer, adopted a 10b5-1 Plan on September 6, 2024. Mr. Mackaness's 10b5-1 Plan provided for the potential sale of up to 60,000 shares of our common stock, and was set to expire on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. Mr. Mackaness terminated this 10b5-1 plan on January 14, 2025.

Kristen Yen, our Senior Vice President, Global Clinical Operations and Patient Advocacy, adopted a 10b5-1 Plan on September 13, 2024. Ms. Yen's 10b5-1 Plan provided for the potential sale of up to 95,089 shares of our common stock, and was set to expire on September 30, 2025, or upon the earlier completion of all authorized transactions thereunder. Ms. Yen terminated this 10b5-1 plan on March 13, 2025.

These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). Certain of our Section 16 Directors or Officers may participate in employee stock purchase plans, 401(k) plans or dividend investment plans of us that have been designed to comply with Rule 10b5-1(c). No "non-Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934) were adopted or terminated by any Section 16 Director or Officer during the three months ended March 31, 2025.

Non-Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Terminated false
Anish Bhatnagar [Member]  
Trading Arrangements, by Individual  
Name Anish Bhatnagar
Title Chief Executive Officer and Chairman of our board of directors
Rule 10b5-1 Arrangement Terminated true
Termination Date January 14, 2025
Expiration Date September 6, 2025
Arrangement Duration 365 days
Aggregate Available 300,000
Jim Mackaness [Member]  
Trading Arrangements, by Individual  
Name Jim Mackaness
Title Chief Financial Officer
Rule 10b5-1 Arrangement Terminated true
Termination Date January 14, 2025
Expiration Date September 6, 2025
Arrangement Duration 365 days
Aggregate Available 60,000
Kristen Yen [Member]  
Trading Arrangements, by Individual  
Name Kristen Yen
Title Senior Vice President
Rule 10b5-1 Arrangement Terminated true
Termination Date March 13, 2025
Expiration Date September 30, 2025
Arrangement Duration 365 days
Aggregate Available 95,089